Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 375 of 496 entries
View as:

Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT00063154 Org: User:
Start: 07/31/03 End: 04/30/05 Due: 04/30/06

A Study to Evaluate the Effect of Particle Size, Formulation and Food on the Pharmacokinetics of GDC-0032 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01980953 Org: User:
Start: 11/30/13 End: 07/31/14 Due: 07/31/15

Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)

Phase: N/A Priority: Normal
NCT ID: NCT00095433 Org: User:
Start: 09/30/02 End: 08/31/06 Due: 08/31/07

A Study of MCAF5352A in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01540760 Org: User:
Start: 03/31/12 End: 09/30/12 Due: 09/30/13

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0941 Following Single Oral Dose Administration in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01474668 Org: User:
Start: 10/31/11 End: 10/31/11 Due: 10/31/12

A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids

Phase: N/A Priority: Normal
NCT ID: NCT00930163 Org: User:
Start: 07/31/09 End: 09/30/10 Due: 09/30/11

A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma

Phase: N/A Priority: Normal
NCT ID: NCT00434434 Org: User:
Start: 10/31/07 End: 06/30/09 Due: 06/30/10

A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02316509 Org: User:
Start: 03/17/15 End: 01/10/20 Due: 01/10/21

An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT02589717 Org: User:
Start: 11/30/15 End: 08/31/16 Due: 08/31/17

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MTRX1011A in Patients With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00718588 Org: User:
Start: 07/31/08 End: - Due: -

A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Phase: N/A Priority: Normal
NCT ID: NCT01209143 Org: User:
Start: 11/30/10 End: 03/31/12 Due: 03/31/13

A Study to Investigate the Relative Bioavailability of Entrectinib Capsule Formulations F1 and F06 Under Fed Conditions in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03796260 Org: User:
Start: 01/09/19 End: 02/04/19 Due: 02/04/20

A Study of GDC-0575 Alone and in Combination With Gemcitabine in Participants With Refractory Solid Tumors or Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01564251 Org: User:
Start: 03/23/12 End: 01/11/18 Due: 01/11/19

Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00074438 Org: User:
Start: 06/30/03 End: 07/31/11 Due: 07/31/12

A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06835465 Org: User:
Start: 02/21/25 End: 05/06/25 Due: 05/06/26

A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors

Phase: N/A Priority: Normal
NCT ID: NCT02162719 Org: User:
Start: 08/19/14 End: 08/31/19 Due: 08/31/20

A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT00079742 Org: User:
Start: 09/30/03 End: 05/31/07 Due: 05/31/08

A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

Phase: N/A Priority: Normal
NCT ID: NCT00876109 Org: User:
Start: 10/31/07 End: 11/30/13 Due: 11/30/14

A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01814709 Org: User:
Start: 04/30/13 End: 08/31/13 Due: 08/31/14

A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)

Phase: N/A Priority: Normal
NCT ID: NCT00473330 Org: User:
Start: 06/30/07 End: 11/30/12 Due: 11/30/13

A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01862081 Org: User:
Start: 07/16/13 End: 06/09/17 Due: 06/09/18

A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00960960 Org: User:
Start: 08/31/09 End: 12/31/15 Due: 12/31/16

A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).

Phase: N/A Priority: Normal
NCT ID: NCT03137069 Org: User:
Start: 05/26/17 End: 10/25/19 Due: 10/25/20

An Absolute Bioavailability Study in Healthy Participants Comparing Oral to Intravenous Administration of GDC-0973 (Cobimetinib)

Phase: N/A Priority: Normal
NCT ID: NCT01249118 Org: User:
Start: 11/30/10 End: 01/31/11 Due: 01/31/12

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Phase: N/A Priority: Normal
NCT ID: NCT03275103 Org: User:
Start: 09/19/17 End: 12/31/25 Due: 12/31/26